Cancer Enzymatic Therapy

Women suffering from recurrent ovarian cancer may have a new treatment regimen that may increase the response to treatment and prolong their lives. Doctors at H. Lee Moffitt Cancer Center & Research Institute are testing a combination of chemotherapy and the drug Avastin in these patients. Moffitt opened a clinical trial recently and is looking for new participants for the study.

"We can often get the cancer to shrink for periods of time, but ultimately, it becomes resistant to standard chemotherapies," said Dr. Robert Wenham, member of the gynecologic oncology program at Moffitt. "The hope is that by using these targeted therapies, we can prolong and manage the cancer making it more of a chronic disease process rather than something that's going to take the patient's life."

The clinical trial will address ovarian cancers that are incurable and tough to treat.

Queen’s new cancer program is well worth the effort

John's Lutheran School and an active coach in basketball, volleyball and track. During what he thought was a routine colonoscopy last August; he was diagnosed with colon cancer.“I was able to teach through the first semester during chemotherapy and radiation, but my first surgery had complications and I was in the hospital for six weeks," said Hauch, 58. “I had liver surgery in May and spent seven days in the hospital."Hauch wants to return to his classroom when school resumes in late August. To ready himself, he's enrolled in the new Cancer Wellness Program at Queen of the Valley Medical Center.“The Cancer Wellness Program has been a two-year project in the making," said Mike Smith, a physical therapist and catalyst for the program. “I've always had an interest in using exercise to relieve pain.

Study Presented at ASCO Shows Encouraging Preliminary Results for ...

VANCOUVER and CARLSBAD, CA, June 2 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. today announced preliminary data from a Phase II clinical trial of OGX-011 in combination with docetaxel and prednisone in patients with metastatic hormone refractory prostate cancer (HRPC). Data were presented by Dr. Kim Chi, Study Chair and a medical oncologist at BC Cancer Agency - Vancouver Centre, representing the National Cancer Institute of Canada - Clinical Trials Group at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Eighty-one patients with metastatic or locally recurrent prostate cancer refractory to hormone therapy were randomized to one of two treatment arms to receive either 640 mg OGX-011 per week in combination with docetaxel and prednisone or docetaxel and prednisone alone.